FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized phase II trial of a monoclonal antibody (mAb) drug
immunoconjugate, SGN-15, administered weekly in combination with weekly docetaxel. The
primary objective of the study is to determine the optimal interval between SGN-15 and
docetaxel using FDG-PET imaging as a surrogate marker of response. In addition, clinical
response rate, duration of response, and survival data will be collected.